During ACR Convergence 2023, experts discussed developments in the treatment and diagnosis of osteoporosis, addressing risks of treatment discontinuation, the use of bone turnover markers in patient assessment and vitamin D.
Search results for: cardiovascular risk
Lifestyle Medicine Interventions Can Benefit Patients with Rheumatic Disease
Lifestyle medicine interventions, such as dietary changes, movement and mindfulness, in combination with conventional treatment, may help alleviate symptoms of rheumatic disease, according to panelists at ACR Convergence 2023.
When a JAK Inhibitor Fails
What Are the Therapeutic Alternatives When a Janus Kinase Inhibitor Fails to Work? SAN DIEGO—Treatment alternatives after Janus kinase (JAK) inhibitor failure in real-life conditions were analyzed and presented at ACR Convergence 2023 by Pablo Francisco Muñoz Martínez, a rheumatologist at the Hospital Universitario y Politécnico La Fe, Sagunto, Spain.1 JAK inhibitors are newer, targeted…
Old Disease, New Tricks: A Novel Approach to Understanding Gout
SAN DIEGO—Gout has sometimes been called the disease of kings, not only because of the fact that purine-rich foods were long affordable only to wealthier individuals, but also because the disease has been around since the monarchies that existed centuries ago. However, with groundbreaking research leading to a better understanding of gout, we can now…
Can SGLT2 Inhibitors Protect Our SLE Patients?
SAN DIEGO—At ACR Convergence 2023, Plenary Session 2, April M. Jorge, MD, shared data concerning the potential cardio- and renal-protective benefits of sodium-glucose co-transporter-2 inhibitors in patients with systemic lupus erythematosus and lupus nephritis.
Clinical Year in Review: 2023
SAN DIEGO—At ACR Convergence 2023, Philip Seo, MD, MHS, presented an overview of clinical updates in rheumatology from the past year.
Top Research in ANCA-Associated Vasculitis Presented at ACR Convergence 2023
SAN DIEGO—Vasculitis expert and former editor of The Rheumatologist, Dr. Philip Seo gives us his picks for the 10 most important abstracts in ANCA-associated vasculitis to come out of ACR Convergence 2023.
The Heterogeneity of Psoriatic Arthritis
SAN DIEGO—Differences between psoriatic arthritis and rheumatoid arthritis highlight the need for the development of imaging modalities, laboratory tests and other biomarkers that are explored and validated specifically for PsA to advance the goal of personalized or precision medicine. In this article, expert David S. Pisetsky, MD, PhD, explores the top research in psoriatic arthritis presented at ACR Convergence 2023.
From Basic Science to Clinical Treatments: An Update on PsA
Dr. Christopher Ritchlin provided insights into the underlying mechanisms of the immune system that promote disease activity in patients with psoriatic arthritis (PsA), the latest research on how to optimize therapy for PsA and more.
The 2023 ACR Awards of Distinction
SAN DIEGO—During ACR Convergence 2023 on Nov. 11, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care by announcing the recipients of the ACR’s 2023 Awards of Distinction, as well as the 2023 ACR Masters who were recognized for their contributions to the field.
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 56
- Next Page »